



PolyNovo Limited
ABN 96 083 866 862

2/320 Lorimer Street
Port Melbourne
VIC Australia 3207

P +61 (0) 3 8681 4050
F +61 (0) 3 8681 4099

28 January 2020

ASX Announcement

UK/Ireland first NovoSorb BTM Surgeries

PolyNovo is pleased to announce NovoSorb BTM been applied to the first two patients in the UK. One patient was treated for Necrotising Fasciitis in an English NHS hospital. A second patient was treated for a scalp defect. Several other NHS hospitals are in the process of selecting patients for surgeries.

In anticipation of the launch in the UK/Ireland, PolyNovo had stock on the ground in England.

Over the past 14 months PolyNovo has been establishing a direct sales infrastructure and business processes in the UK to be ready for the anticipated demand for NovoSorb BTM.

We are pleased to announce the appointment of two additional sales staff for the UK and Ireland and the recruitment of a Marketing Manager for UK and Europe who will be based in England. The new staff are being inducted and trained and expected to be in the field by March.

Further update on Europe

As a further update on Europe, further surgeries have happened in Switzerland and Germany since our release on 22 January. Our distributor, PMI, has also placed a second order.

PolyNovo's CEO, Mr Paul Brennan said, *"We have now achieved first surgeries in England, Germany and Switzerland. Last week I visited several surgeons with our UK Sales Manager and I was impressed by the excitement that NovoSorb has generated. The first surgeries in England so soon after registration are a reflection of doctor enthusiasm."*

PolyNovo's Chairman, Mr David Williams said, *"We have a lot of work to do building our base from these early patients and in the meantime sales will be lumpy. We are also looking for good sales staff in many parts of Western Europe to make the most of our EU approval."*

This announcement has been authorised by Company Secretary Mr. Jan-Marcel Gielen.

Further information:

Paul Brennan
Chief Executive Officer
Mobile +61 427 662 317

David Williams
Chairman
Mobile +61 414 383 593

About NovoSorb®

NovoSorb is a novel range of bio-resorbable polymers that can be produced in many formats including, film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and programmable bio-resorption profile. NovoSorb BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery or burn.

About PolyNovo®

PolyNovo is an Australian based medical device company that designs, develops and manufactures dermal regeneration solutions (NovoSorb BTM) using its patented NovoSorb biodegradable polymer technology. Our development program covers Breast Sling, Hernia, and Orthopaedic applications. For further information and market presentations see www.polynovo.com.au

About PolyMedics®

Headquartered in Germany, PMI has become a market leader for biosynthetic epidermal skin substitutes. PMI is committed to offering the most innovative solutions to its burn and wound care customers. PolyMedics is the manufacturer and marketer of Suprathel wound dressing. Suprathel is an absorbable, microporous membrane and alloplastic skin substitute for the treatment of wounds, split-skin donor sites and burns. <http://www.polymedics.de>